Market Analysis

Infectious Market is largely segmented into the Diagnostics and the Therapeutics, which is further segmented into interventional such as drugs and preventive such as vaccines.

The global infectious disease treatment market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs and antiparasitic drugs. Antibacterial drugs segment covers tetracyclines, beta-lactams, aminoglycosides, macrolides, phenicols, sulfonamides and quinolones. Antifungal segment includes azoles, echinodians, pyrimidines, polyenes and allylamines. Antiviral drugs segment covers HIV, hepatitis B and C treatment drugs.

Increasing prevalence of the infectious diseases is key driving factor for the global infectious disease treatment market. Increasing awareness and extensive R&D drugs pipelines are also enhancing the growth of global infectious disease market. Moreover, introduction of novel drugs, such as direct-acting antivirals, boosts the growth of global infectious disease treatment market.
However, patent expiry of various major drugs and presence of generic drugs are key restraint of the global infectious disease treatment market. Stringent regulations and legislations and side-effects of anti-infective drugs also hinder the growth of global infectious disease treatment market. Rapid product launches and increasing mergers and acquisitions between drug manufactures are emerging trends of the global infectious disease treatment market.

The global infectious disease diagnostics market

The global infectious disease diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to reach 41.6 billion by 2027. The growth is primarily attributed to prevalence of infectious diseases, global outbreak of COVID-19, technological advancements, and increased demands for decentralized diagnostic POC kits. However, unfavourable and inadequate reimbursement scenarios can impact the growth of the market.

Reagents, kits and consumables segment accounted for the largest share of infectious disease diagnostics market. The largest share of this segment is mainly attributed to frequent purchase of these products due to their recurrent usage.
By type of testing, infectious disease diagnostics market is segmented into laboratory testing and POC testing. During the forecast period, POC testing accounted for fastest growth. Highest CAGR can be attributed to faster diagnosis and need to closely monitor patients.
On the basis of technology, infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays and other technologies. Immunodiagnostics segment accounted for largest share in 2020. The growth of this segment was mainly attributed to increasing demand for immunoassays in COVID-19 testing, POC infectious disease testing, rising trend for automation and development of immunodiagnostic tests.
By disease type, hepatitis segment held the largest share of infectious disease diagnostics market in 2020. The growth is mainly driven by increasing blood transfusions and donations, prevalence of hepatitis B & C infections, rising geriatric population and benefits offered by POC instruments and kits.
By end user, diagnostic laboratory segment accounted for highest CAGR. This can be attributed to strengthening of healthcare infrastructure and prevalence of infectious disease.
Key Market Players in the infectious disease diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMerieux SA, Thermo Fisher Scientific Inc., Danaher Corporation, Quidel Corporation, Hologic, Inc., Siemens Healthineers AG, Becton, Dickinson and Company, PerkinElmer Inc., QIAGEN, Grifols S.A., DiaSorin S.p.A, Bio-Rad Laboratories Inc., Sysmex Corporation, Ortho Clinical Diagnostics, Luminex Corporation, Meridian Bioscience, Genetic Signatures, OraSure Technologies, Trinity Biotech Plc., Chembio Diagnostic Systems Inc., Seegene Inc., Co-Diagnostics Inc., ELITechGroup (France), Epitope Diagnostics, Inc., Trivitron Healthcare, Meril Life Sciences Pvt. Ltd., InBios International Inc. and ABACUS Diagnostica Oy.

Anti-Infective Drugs Market Dynamics

• The global anti-infective drugs market market growth is driven by the rise awareness among the population about various infectious diseases and the availability of reimbursements to infection treatment in various countries have played a significant role in driving the market. Rise in the number of hospitals and primary care clinics drive the demand for anti-infective drugs.

• Factors like increasing prevalence of infectious diseases and antimicrobial resistance to existing anti-infective agents are estimated to fuel the market growth. Moreover, escalating health-consciousness, about the availability of diagnostics for infectious diseases and avoidable risks associated with the early diagnosis are some of the factors projected to boost the growth.

• Over the past two decades, the infection rate has grown significantly, particularly across the low and middle income countries. There are a large number of companies well-established in the market with their products in the form of antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals targeting cytochrome, interleukin, interferons and some are multi-drug resistants.

• Increase in hyperlipidemia cases expected to drive the market growth.

• However, one of the major restraints to this market are high investment costs in R&D, as major importance is given to multi-drug resistant drug, where several companies product fail in the early-stage or clinical stage of development. Also, shortage of resources in healthcare facilities particularly in emerging markets, restricts the growth of this market.

• COVID-19 was may have a complex long-term impact on anti-infective resistance. Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on anti-infective and on access to effective antimicrobials. However, the impact of covid-19 on the pharmaceutical industry is projected to be neutralized by certain factors including higher demand for currently marketed drugs including anti-infective.

• The antiviral agents are expected to show high growth, as several drug manufacturers are exploring the opportunities to expand in the lower and middle income countries, where epidemic infection rate is high. There is high diversity in patient pool which require long treatment procedures in hospital facilities as well as home care treatments.

• The hospital pharmacies held the largest share in the Anti-Infective drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

• The anti-infective drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Panacea Biotech Ltd., Novartis AG, Pfizer Ltd., Ranbaxy Laboratories Ltd., and Sun Pharmaceutical Industries Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anti-infective drugs market globally.

Ref: